SSG
CORT icon

Summit Securities Group’s Corcept Therapeutics CORT Stock Holding History

Summit Securities Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,153
Closed -$231K – 1082
2025
Q2 		$231K Buy
+3,153
New +$229K 0.04% 243
2024
Q4 		– Sell
-197
Closed -$9K – 683
2024
Q3 		$9K Buy
+197
New +$7K ﹤0.01% 385

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Summit Securities Group's CORT Position: Q3 2025 in Review

Summit Securities Group sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 3,153 shares — an estimated $231K sold.

Summit Securities Group first reported a position in CORT in Q3 2024 and held it in 2 quarters. The position peaked at $231K in Q2 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Summit Securities Group reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Summit Securities Group sold 3,153 Corcept Therapeutics shares in Q3 2025, an estimated $231K.
  • Summit Securities Group first reported a position in Corcept Therapeutics in Q3 2024 and held it in 2 quarters.
  • Summit Securities Group's Corcept Therapeutics position peaked at $231K in Q2 2025.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Summit Securities Group's 13F filing for Q3 2025, filed 13 Nov 2025.